title: Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.
abstract: A total of 1050 patients with differentiated thyroid cancer (DTC) have been followed in the Thyroid Center of Padua by means of serum thyroglobulin (Tg) measured with IRMA method and anti-Tg antibodies (TgAb) assays. Circulating TgAbs were detected in 102 (9.7%) patients. In 32 of these 102, TgAbs were evaluated before and after total thyroidectomy and 131I ablation. In these patients no relationship was found between preoperative serum TgAb levels on the one hand and tumor stage at diagnosis or outcome of the disease on the other. During the follow-up, TgAb serum levels decreased or disappeared in 21 cases considered tumor-free, while they remained unchanged or even increased, in comparison with the preoperative ones, in 11 patients, 5 with proven metastases and 6 considered tumor-free. Evaluating the whole group of 102 TgAb-positive patients, we observed that TgAb serum levels, measured after thyroid ablation, were significantly higher in cases with metastases than in those considered tumor-free (653.0 +/- 196.9 vs 157.7 +/- 116.5 U/ml, m +/- SD, p less than 0.0001). In the group of patients with metastases and circulating TgAbs, Tg serum levels were elevated in 27% of cases on TSH-suppressive therapy and in 44% off therapy when nodal metastases were present, and in 67% of cases on TSH-suppressive therapy and in 83% off therapy when distant metastases were present.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di Semeiotica Medica, University of Padova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Rubello
authors.forename: M E
authors.initials: ME
authors.lastname: Girelli
authors.forename: D
authors.initials: D
authors.lastname: Casara
authors.forename: M
authors.initials: M
authors.lastname: Piccolo
authors.forename: A
authors.initials: A
authors.lastname: Perin
authors.forename: B
authors.initials: B
authors.lastname: Busnardo
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002291:Carcinoma, Papillary / Q000097:blood / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015592:Immunoradiometric Assay; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D013954:Thyroglobulin / Q000097:blood* / Q000276:immunology; D013964:Thyroid Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D013954:Thyroglobulin